Physician profile
Mala Singh
NPI 1265546154
$990.30
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $668.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $196.98 | 2019-2020 | |
| Novo Nordisk INC | $128.81 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.59 | 2019-2020 | |
| Allergan, INC. | $84.66 | 2019-2020 | |
| Astellas Pharma US INC | $68.11 | 2019-2020 | |
| Glaxosmithkline, LLC. | $62.45 | 2019-2020 | |
| Pfizer INC. | $55.58 | 2019-2020 | |
| Lilly USA, LLC | $47.62 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $36.87 | 2019-2020 | |
| Ibsa Pharma INC. | $27.61 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $27.44 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $24.32 | 2019 | |
| Endo Pharmaceuticals INC. | $20.07 | 2020 | |
| Merck Sharp & Dohme LLC | $19.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $17.50 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $17.40 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $17.01 | 2019 | |
| Antares Pharma, INC. | $16.73 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.70 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mala Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.